Study in Patients With Asthma

The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

5 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Site, Little Rock, Arkansas, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Children with a history of asthma
Written guardian approval

Exclusion criteria

Current or recent asthma exacerbation, requiring hospitalization
History of smoking
Debilitating or systemic and/or life-threatening diseases.

Treatment and study plan

formoterol fumarate

Drug

Primary outcomes

Measure of lung function

Secondary outcomes

Change in lung function, as well as vital signs
Physical Exam results, AE reporting, etc

Sponsors and collaborators

Lead sponsor

Dey

Industry

Registry information

Important dates

Primary completion: 2003
Study completion: 2005
First posted: Sep 22, 2005
Registry last updated: Nov 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed